- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00423917
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Fulvestrant and bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving fulvestrant together with bevacizumab may be an effective treatment for metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving fulvestrant together with bevacizumab works in treating patients with metastatic breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Assess the efficacy of fulvestrant and bevacizumab, in terms of 6-month progression-free survival (PFS), in patients with metastatic breast cancer previously treated with an aromatase inhibitor.
Secondary
- Assess the quality of life of patients treated with this regimen.
- Determine the adverse-event profile in these patients.
- Determine the PFS and overall survival of these patients.
- Determine the confirmed response rate, duration of response, time to treatment failure, and time to first cytotoxic agent in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.
After completion of study treatment, patients are followed every 3-6 months for 5 years.
PROJECTED ACCRUAL: A total of 51 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259-5499
- Mayo Clinic Scottsdale
-
-
Florida
-
Hollywood, Florida, United States, 33021
- Memorial Cancer Institute at Memorial Regional Hospital
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic - Jacksonville
-
-
Illinois
-
Aurora, Illinois, United States, 60504
- Rush-Copley Cancer Care Center
-
Bloomington, Illinois, United States, 61701
- St. Joseph Medical Center
-
Canton, Illinois, United States, 61520
- Graham Hospital
-
Carthage, Illinois, United States, 62321
- Memorial Hospital
-
Effingham, Illinois, United States, 62401
- St. Anthony's Memorial Hospital
-
Eureka, Illinois, United States, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Cottage Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Clinic, PC
-
Galesburg, Illinois, United States, 61401
- InterCommunity Cancer Center of Western Illinois
-
Havana, Illinois, United States, 62644
- Mason District Hospital
-
Hopedale, Illinois, United States, 61747
- Hopedale Medical Complex
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, Limited - West
-
Macomb, Illinois, United States, 61455
- Mcdonough District Hospital
-
Moline, Illinois, United States, 61265
-
Moline, Illinois, United States, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
Normal, Illinois, United States, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, United States, 61761
- Community Cancer Center
-
Ottawa, Illinois, United States, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, United States, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, United States, 61554
- Cancer Treatment Center at Pekin Hospital
-
Peoria, Illinois, United States, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, United States, 61614
- Proctor Hospital
-
Peoria, Illinois, United States, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, United States, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peoria, Illinois, United States, 61615-7827
- OSF St. Francis Medical Center
-
Peru, Illinois, United States, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, United States, 61356
- Perry Memorial Hospital
-
Spring Valley, Illinois, United States, 61362
- St. Margaret's Hospital
-
Spring Valley, Illinois, United States, 61362
- Valley Cancer Center
-
Urbana, Illinois, United States, 61801
- Carle Cancer Center at Carle Foundation Hospital
-
Urbana, Illinois, United States, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Beech Grove, Indiana, United States, 46107
- St. Francis Hospital and Health Centers - Beech Grove Campus
-
Michigan City, Indiana, United States, 46360
- Saint Anthony Memorial Health Centers
-
Richmond, Indiana, United States, 47374
- Reid Hospital & Health Care Services
-
-
Iowa
-
Ames, Iowa, United States, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, United States, 52722
-
Cedar Rapids, Iowa, United States, 52403
- Cedar Rapids Oncology Associates
-
Des Moines, Iowa, United States, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, United States, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, United States, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, United States, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, United States, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Des Moines, Iowa, United States, 50307
- Mercy Capitol Hospital
-
Mason City, Iowa, United States, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Sioux City, Iowa, United States, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, United States, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, United States, 51104
- Mercy Medical Center - Sioux City
-
-
Kansas
-
Chanute, Kansas, United States, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, United States, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, United States, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Kingman, Kansas, United States, 67068
- Cancer Center of Kansas, PA - Kingman
-
Liberal, Kansas, United States, 67901
- Southwest Medical Center
-
Newton, Kansas, United States, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, United States, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, United States, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, United States, 67042
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, United States, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, United States, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, United States, 67214
- CCOP - Wichita
-
Wichita, Kansas, United States, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, United States, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, United States, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Adrian, Michigan, United States, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Dearborn, Michigan, United States, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, United States, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, United States, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, United States, 49201
- Foote Memorial Hospital
-
Lambertville, Michigan, United States, 48144
- Haematology-Oncology Associates of Ohio and Michigan, PC
-
Lansing, Michigan, United States, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, United States, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, United States, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, United States, 48162
- Mercy Memorial Hospital - Monroe
-
Pontiac, Michigan, United States, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, United States, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Warren, Michigan, United States, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Alexandria, Minnesota, United States, 56308
-
Bemidji, Minnesota, United States, 56601
- MeritCare Bemidji
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, United States, 55805
- CCOP - Duluth
-
Duluth, Minnesota, United States, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, United States, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fergus Falls, Minnesota, United States, 56537
-
Fridley, Minnesota, United States, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, United States, 55350
- Hutchinson Area Health Care
-
Litchfield, Minnesota, United States, 55355
- Meeker County Memorial Hospital
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, United States, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, United States, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, United States, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, United States, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, United States, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital Cancer Care Center
-
Saint Paul, Minnesota, United States, 55102
- HealthEast Cancer Care at St. Joseph's Hospital
-
Shakopee, Minnesota, United States, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
Woodbury, Minnesota, United States, 55125
- HealthEast Cancer Care at Woodwinds Health Campus
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Missouri Baptist Cancer Center
-
Saint Louis, Missouri, United States, 63141
- Arch Medical Services, Incorporated at Center for Cancer Care and Research
-
-
Montana
-
Billings, Montana, United States, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, United States, 59101
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Billings, Montana, United States, 59101
- Northern Rockies Radiation Oncology Center
-
Billings, Montana, United States, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, United States, 59107-7000
- Billings Clinic - Downtown
-
Bozeman, Montana, United States, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, United States, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, United States, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, United States, 59405
-
Helena, Montana, United States, 59601
- St. Peter's Hospital
-
Kalispell, Montana, United States, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, United States, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, United States, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, United States, 59801
- Community Medical Center
-
Missoula, Montana, United States, 59804
- Guardian Oncology and Center for Wellness
-
Missoula, Montana, United States, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, United States, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, United States, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, United States, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, United States, 68131-2197
- Creighton University Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, United States, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, United States, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, United States, 58502
- St. Alexius Medical Center Cancer Center
-
Fargo, North Dakota, United States, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, United States, 58122
- MeritCare Broadway
-
-
Ohio
-
Bellefontaine, Ohio, United States, 43311
- Mary Rutan Hospital
-
Bowling Green, Ohio, United States, 43402
- Wood County Oncology Center
-
Chillicothe, Ohio, United States, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, United States, 43214-3998
- Riverside Methodist Hospital Cancer Care
-
Columbus, Ohio, United States, 43222
- Mount Carmel Health - West Hospital
-
Columbus, Ohio, United States, 43215
- CCOP - Columbus
-
Columbus, Ohio, United States, 43215
- Grant Medical Center Cancer Care
-
Columbus, Ohio, United States, 43228
- Doctors Hospital at Ohio Health
-
Dayton, Ohio, United States, 45428
- Veterans Affairs Medical Center - Dayton
-
Dayton, Ohio, United States, 45405
- Grandview Hospital
-
Dayton, Ohio, United States, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, United States, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, United States, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, United States, 45429
- CCOP - Dayton
-
Delaware, Ohio, United States, 43015
- Grady Memorial Hospital
-
Findlay, Ohio, United States, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, United States, 45005-1066
- Middletown Regional Hospital
-
Kettering, Ohio, United States, 45429
- Charles F. Kettering Memorial Hospital
-
Lancaster, Ohio, United States, 43130
- Fairfield Medical Center
-
Lima, Ohio, United States, 45804
- Lima Memorial Hospital
-
Marietta, Ohio, United States, 45750
- Strecker Cancer Center at Marietta Memorial Hospital
-
Maumee, Ohio, United States, 43537
- Northwest Ohio Oncology Center
-
Maumee, Ohio, United States, 43537
- St. Luke's Hospital
-
Newark, Ohio, United States, 43055
- Licking Memorial Cancer Care Program at Licking Memorial Hospital
-
Oregon, Ohio, United States, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, United States, 43616
- Toledo Clinic - Oregon
-
Sandusky, Ohio, United States, 44870
- Firelands Regional Medical Center
-
Sandusky, Ohio, United States, 44870
- North Coast Cancer Care, Incorporated
-
Springfield, Ohio, United States, 45505
- Community Hospital of Springfield and Clark County
-
Springfield, Ohio, United States, 45504
- Mercy Medical Center
-
Sylvania, Ohio, United States, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, United States, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, United States, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
Toledo, Ohio, United States, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, United States, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Troy, Ohio, United States, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wauseon, Ohio, United States, 43567
- Fulton County Health Center
-
Westerville, Ohio, United States, 43081
- Mount Carmel St. Ann's Cancer Center
-
Wilmington, Ohio, United States, 45177
- Clinton Memorial Hospital
-
Xenia, Ohio, United States, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
Zanesville, Ohio, United States, 43701
- Genesis - Good Samaritan Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
Danville, Pennsylvania, United States, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
Hazleton, Pennsylvania, United States, 18201
- Geisinger Hazleton Cancer Center
-
State College, Pennsylvania, United States, 16801
- Geisinger Medical Group - Scenery Park
-
Wilkes-Barre, Pennsylvania, United States, 18711
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
-
Wilkes-Barre, Pennsylvania, United States, 18765
- Mercy Hospital at Wilkes-Barre
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, United States, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, United States, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Marinette, Wisconsin, United States, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, United States, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sturgeon Bay, Wisconsin, United States, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Wyoming
-
Sheridan, Wyoming, United States, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed breast cancer
- Metastatic disease
- Must have received an aromatase inhibitor (e.g., letrozole, anastrozole, or exemestane) in an adjuvant or metastatic setting
- If tumor is HER2 positive (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization) the patient must have received ≥ 1 prior trastuzumab (Herceptin®)-containing regimen unless there is a contraindication to trastuzumab
Measurable or nonmeasurable disease, including any of the following :
- Bone metastasis
- Pleural/pericardial effusion
- Ascites
- Inflammatory skin changes
- No microscopic residual disease only
- Enrolled on or refused enrollment on clinical trial NCCTG-N0392
No evidence of active brain metastasis including leptomeningeal involvement
- CNS metastasis controlled (i.e., at least 2 months of no symptoms or evidence of progression) by prior surgery and/or raditherapy are allowed
Hormone receptor status:
- Estrogen and/or progesterone receptor-positive tumor
PATIENT CHARACTERISTICS:
- Male or female
Female patients must be post-menopausal based on any 1 of the following criteria:
- Age ≥ 60 years
- Age ≥ 45 years with last menstrual period ≥ 12 months prior to study entry
- Estradiol and follicle-stimulating hormone levels in postmenopausal range
- History of bilateral oophorectomy
- ECOG performance status 0-2
- Life expectancy > 3 months
- Fertile patients must use effective contraception during and for 30 days after completion of study treatment
- WBC ≥ 3,000 mg/dL
- Hemoglobin > 8 g/dL
- Absolute neutrophil count > 1,000/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN
Urine protein < 1+ OR < 1 g of protein by 24-hour urine collection
- No nephrotic syndrome
No uncontrolled hypertension (i.e., blood pressure [BP] > 160/90 mm Hg on ≥ 2 occasions at least 5 minutes apart)
- Patients who have recently started or adjusted antihypertensive medications are eligible provided BP is < 140/90 mm Hg on any new regimen for ≥ 3 different observations in ≥ 14 days
No clinically significant cardiac disease, including any of the following:
- Congestive heart failure
- Symptomatic coronary artery disease
- Unstable angina
- Cardiac arrhythmias not well controlled with medication
- Myocardial infarction within the past 12 months
- No arterial or venous thrombosis within the past 12 months
- No hemoptysis or gastrointestinal hemorrhage within the past 6 months
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 4 weeks
- No significant traumatic injury within the past 4 weeks
- No active, unresolved infection
- No history of hypertensive crisis or hypertensive encephalopathy
- No history of bleeding diathesis or uncontrolled coagulopathy
- No history of cerebrovascular accident, hemorrhage, or stroke
- No allergy or hypersensitivity to drug product excipients, murine antibodies, or agents chemically similar to study drugs
- No other malignancy within the past 3 years except for basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No other serious medical condition that would preclude study therapy or compliance
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior radiotherapy to a target lesion allowed provided there has been clear progression since radiotherapy was completed
At least 4 weeks since prior radiotherapy
- Single-dose radiation for palliation or to a nontarget lesion only allowed within the past 4 weeks
- No more than 1 prior chemotherapy regimen for metastatic disease
- No more than 2 prior endocrine (hormonal) therapy regimens in the neoadjuvant, adjuvant, or metastatic setting
- At least 4 weeks since prior major surgery or open biopsy
- At least 4 weeks since prior chemotherapy or immunologic therapy
At least 2 weeks since prior and no concurrent use of any of the following agents:
- Aspirin (daily low-dose [81 mg] aspirin allowed])
- Thrombolytic agents
- Anticoagulants (low-dose anticoagulation therapy to maintain patency of a vascular access device is allowed)
- No concurrent treatment in another clinical study with investigational procedures or investigational therapies
- No other concurrent anticancer therapy, including chemotherapy, biologic agents, or radiotherapy
- No routine use of granulocyte colony-stimulating factors during course 1
- No concurrent oprelvekin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fulvestrant + bevacizumab
Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment. After completion of study treatment, patients are followed every 3-6 months for 5 years. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six-month Progression-free Survival (PFS) Rate at 6 Months
Time Frame: at 6 months
|
The primary endpoint of this trial is the 6-month progression-free survival rate.
A patient is considered to be a 6-month progression-free survivor if the patient is on study treatment 6 months from registration without a documentation of disease progression.
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
Additionally, if some patients are lost to follow-up not having been observed for at least 6 months, an estimate and 95% confidence interval for the 6-month progression-free survival rate incorporating censoring will be computed using the method of Kaplan-Meier.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: Up to 5 years
|
Time to disease progression is defined as the time from registration to the earliest date of documentation of disease progression.
If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death.
If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred.
In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression 1 day post-registration.
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
Up to 5 years
|
Overall Survival
Time Frame: Up to 5 years
|
Survival time is defined as the time from registration to death due to any cause.
The distribution of survival time will be estimated using the method of Kaplan-Meier (1958).
|
Up to 5 years
|
Quality of Life, as Measured by the Largest Mean Change in LASA Overall QOL and Physical Well-being Items
Time Frame: Up to 5 years
|
Quality of life (QOL) assessment will be a secondary exploratory component of this trial.
QOL of patients was measure using the 6-item Linear Analogue Self-Assessment (LASA).The LASA consists of six single-item numeric analog scales measuring overall QOL; mental, physical, emotional, and spiritual well-being; and level of activity each on a scale of 0 ('As bad as it can be') to 10 ('As good as it can be') during the past week.
Items were transformed to a 0 (worst QOL or well-being) to 100 (best QOL or well-being) scale for statistical analysis.
Mean change from baseline of the largest mean change in overall QOL and physical well-being are reported below.
|
Up to 5 years
|
Objective Response Rate as Measured by RECIST Criteria in Patients With Measurable Disease
Time Frame: Up to 5 years
|
A confirmed response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart.
The confirmed response rate will be estimated by the number of confirmed responses in evaluable patients with measurable disease divided by the total number of evaluable patients with measurable disease.
The appropriate confidence interval will be calculated.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Up to 5 years
|
Time to First Cytotoxic Agent
Time Frame: Up to 5 years
|
Time to first dose of a cytotoxic agent is defined to be the time from the date of registration to the date at which a patient recieves the first dose of a cytotoxic agent.
The distribution of time to first dose of a cytotoxic agent will be estimated using the method of Kaplan-Meier (1958).
|
Up to 5 years
|
Duration of Response/Time to Disease Progression in Patients With Measurable Disease
Time Frame: Up to 5 years
|
Duration of response is defined for all evaluable patients with measurable disease who have achieved a confirmed response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented.
If a patient dies subsequent to the confirmed response without a documentation of disease progression, the patient will be considered to have had disease progression at the time of their death.
In the case of a patient failing to return for evaluations before a documentation of disease progression, the patient will be censored for progression on the date of last evaluation.
The distribution of duration of response will be estimated using the method of Kaplan-Meier.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
Up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Winston Tan, MD, FACP, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Bevacizumab
Other Study ID Numbers
- NCCTG-N0539
- NCI-2009-00649 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000525570 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditionsUnited States